Molecular basis of carcinogenesis in diabetic patients (Review)

International Journal of Oncology

Volumn 46, Issue 4, 2015, Pages 1435-1443

  Matyszewski, Artur ^a,b,c   Czarnecka, Anna M ^a   Solarek, Wojciech ^a,d   Korzeñ, Piotr ^a   Safir, Ilan J ^e   Kukwa, Wojciech ^d   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b Department of Internal Medicine   (Poland)

^c L Rydygier Voivodeship Hospital   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinogenesis; Diabetes; Insulin resistance; Metabolic disorders; Obesity

Indexed keywords

GLUCOSE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; GLUCOSE BLOOD LEVEL;

BREAST CANCER; BREAST CARCINOGENESIS; CARCINOGENESIS; CELLULAR IMMUNITY; COLORECTAL CANCER; DIABETES MELLITUS; DIABETIC PATIENT; DISORDERS OF CARBOHYDRATE METABOLISM; ENDOMETRIUM CANCER; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; IMMUNE SYSTEM; INSULIN RESISTANCE; LIVER CANCER; LIVER CARCINOGENESIS; LUNG CANCER; LUNG CARCINOGENESIS; MOLECULAR PATHOLOGY; NEOPLASM; OBESITY; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; ANIMAL; CELL TRANSFORMATION; FEMALE; GLUCOSE BLOOD LEVEL; IMMUNOLOGY; MALE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD GLUCOSE; CELL TRANSFORMATION, NEOPLASTIC; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84923086755     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2865     Document Type: Review

References (89)

1. PIATKIEWICZ P and CZECH A: Glucose metabolism disorders and the risk of cancer. Arch Immunol Ther exp (warsz) 59: 215-230, 2011.
2. BERGAMINI E, CAVALLINI G, DONATI A and GORI Z: The role of autophagy in aging: Its essential part in the anti-aging mechanism of caloric restriction. Ann NY Acad Sci 1114: 69-78, 2007.
3. DE MEYTS P: The structural basis of insulin and insulin-like growth factor-i receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia 37 (Suppl 2): S135-S148, 1994.
4. JENSEN M and DE MEYTS P: Molecular mechanisms of differential intracellular signaling from the insulin receptor. Vitam horm 80: 51-75, 2009.
5. HERMANN C, ASSMUS B, URBICH C, ZEIHER AM and DIMMELER S: Insulin-mediated stimulation of protein kinase akt: A potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 20: 402-409, 2000.
6. HWA V, OH Y and ROSENFELD RG: The insulin-like growth factor-binding protein (igfBP) superfamily. Endocr Rev 20: 761-787, 1999.
7. HOLLY J and PERKS C: The role of insulin-like growth factor binding proteins. Neuroendocrinology 83: 154-160, 2006.
8. JONES JI and CLEMMONS DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16: 3-34, 1995.
9. WERNER H, WEINSTEIN D and BENTOV I: Similarities and differences between insulin and igf-i: Structures, receptors, and signalling pathways. Arch Physiol Biochem 114: 17-22, 2008.
10. LEE PD, GIUDICE LC, CONOVER CA and POWELL DR: Insulin-like growth factor binding protein-1: Recent findings and new directions. Proc Soc Exp Biol Med 216: 319-357, 1997.
11. GUM RJ, GAEDE LL, KOTERSKI SL, et al: Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 52: 21-28, 2003.
12. TANIGUCHI CM, EMANUELLI B and KAHN CR: Critical nodes in signalling pathways: Insights into insulin action. Nat Rev Mol Cell Biol 7: 85-96, 2006.
13. UEKI K, KONDO T and KAHN CR: Suppressor of cytokine signaling 1 (SocS-1) and SocS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24: 5434-5446, 2004.
14. UEKI K, KONDO T, TSENG YH and KAHN CR: Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc natl Acad Sci uSa 101: 10422-10427, 2004.
15. EMANUELLI B, PERALDI P, FILLOUX C, SAWKA-VERHELLE D, HILTON D and VAN OBBERGHEN E: SocS-3 is an insulin-induced negative regulator of insulin signaling. J Biol chem 275: 15985-15991, 2000.
16. EMANUELLI B, PERALDI P, FILLOUX C, et al: SocS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol chem 276: 47944-47949, 2001.
17. WICK KR, WERNER ED, LANGLAIS P, et al: Grb10 inhibits insulin-stimulated insulin receptor substrate (irS)-phosphatidylinositol 3-kinase/akt signaling pathway by disrupting the association of irS-1/irS-2 with the insulin receptor. J Biol chem 278: 8460-8467, 2003.
18. DONG H, MADDUX BA, ALTOMONTE J, et al: Increased hepatic levels of the insulin receptor inhibitor, Pc-1/nPP1, induce insulin resistance and glucose intolerance. Diabetes 54: 367-372, 2005.
19. KELLERER M, VON EYE CORLETA H, MÜHLHÖFER A, et al: Insulin-and insulin-like growth-factor-i receptor tyrosine-kinase activities in human renal carcinoma. Int J Cancer 62: 501-507, 1995.
20. CORLETA HE, CAPP E and CORLETA OC: Insulin receptor tyrosine kinase activity in colon carcinoma. Braz J Med Biol res 29: 1593-1597, 1996.
21. WERNER H and LE ROITH D: New concepts in regulation and function of the insulin-like growth factors: Implications for understanding normal growth and neoplasia. Cell Mol life Sci 57: 932-942, 2000.
22. YI HK, HWANG PH, YANG DH, KANG CW and LEE DY: Expression of the insulin-like growth factors (igfs) and the igf-binding proteins (igfBPs) in human gastric Cancer cells. Eur J Cancer 37: 2257-2263, 2001.
23. HUDELIST G, WAGNER T, ROSNER M, et al: Intratumoral igf-i protein expression is selectively upregulated in breast Cancer patients with Brca1/2 mutations. Endocr Relat Cancer 14: 1053-1062, 2007.
24. KIM WY, JIN Q, OH SH, et al: Elevated epithelial insulin-like growth factor expression is a risk factor for lung Cancer development. Cancer Res 69: 7439-7448, 2009
25. WERNER H and BRUCHIM I: The insulin-like growth factor-. receptor as an oncogene. Arch Physiol Biochem 115: 58-71, 2009
26. VELLA V, PANDINI G, SCIACCA L, et al: A novel autocrine loop involving iGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87: 245-254, 2002.
27. BOULLE N, LOGIÉ A, GICQUEL C, PERIN L and LE BOUC Y: Increased levels of insulin-like growth factor II (iGF-II) and iGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 83: 1713-1720, 1998.
28. MOOREHEAD RA, SANCHEZ OH, BALDWIN RM and KHOKHA R: Transgenic overexpression of iGF-II induces spontaneous lung tumors: A model for human lung adenocarcinoma. Oncogene 22: 853-857, 2003.
29. LEE JS, WEISS J, MARTIN JL and SCOTT CD: Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast Cancer cells alters tumorigenic properties in vitro and in vivo. Int J Cancer 107: 564-570, 2003.
30. HEBERT E: Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci rep 26: 7-17, 2006.
31. EL-SHEWY HM and LUTTRELL LM: Insulin-like growth factor-2/mannose-6 phosphate receptors. Vitam horm 80: 667-697, 2009
32. LARSSON O, GIRNITA A and GIRNITA L: Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92: 2097-2101, 2005
33. LEROITH D and ROBERTS CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137, 2003.
34. FRASCA F, PANDINI C, SCIACCA L, et al: The role of insulin receptors and iGF-i receptors in Cancer and other diseases. Arch Physiol Biochem 114: 23-37, 2008.
35. GODSLAND IF: Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (lond) 118: 315-332, 2009
36. RENEHAN AG, ZWAHLEN M, MINDER C, O'DWYER ST, SHALET SM and EGGER M: Insulin-like growth factor (igf)-i, igf binding protein-3, and Cancer risk: Systematic review and meta-regression analysis. Lancet 363: 1346-1353, 2004
37. IHLE NT and POWIS G: Take your P. K: Phosphatidylinositol 3-kinase inhibitors race through the clinic and toward Cancer therapy. Mol Cancer Ther 8: 1-9, 2009
38. ROBEY RB and HAY T: Is akt the 'warburg kinase'-akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 19: 25-31, 2009
39. COURTNEY KD, CORCORAN RB and ENGELMAN JA: The Pi3K pathway as drug target in human cancer. J Clin oncol 28: 1075-1083, 2010.
40. JENAB M, RIBOLI E, CLEVELAND RJ, et al: Serum c-peptide, igfBP-1 and igfBP-2 and risk of colon and rectal cancers in the european Prospective investigation into Cancer and nutrition. Int J Cancer 121: 368-376, 2007
41. WEI EK, MA J, POLLAK MN, et al: A prospective study of c-peptide, insulin-like growth factor-i, insulin-like growth factor binding protein-1, and the risk of colorectal Cancer in women. Cancer epidemiol Biomarkers Prev 14: 850-855, 2005
42. KAAKS R, TONIOLO P, AKHMEDKHANOV A, et al: Serum c-peptide, insulin-like growth factor (igf)-i, IGF-binding proteins, and colorectal Cancer risk in women. Igf Atl Cancer inst 92: 1592-1600, 2000.
43. MA J, C IOVANNUCCI E, POLLAK M, et al: A prospective study of plasma-peptide and colorectal Cancer risk in men. J Natl Cancer Inst 96: 546-553, 2004
44. SCHOEN RE, TANGEN CM, KULLER LH, et al: Increased blood glucose and insulin, body size, and incident colorectal cancer. Atl Cancer Inst 91: 1147-1154, 1999
45. J N E MARCHAND L, WANG H, RINALDI S, et al: Associations of plasma l-peptide and igfBP-1 levels with risk of colorectal adenoma in a multiethnic population. Cancer Epidemiol Biomarkers Prev 19: 1471-1477, 2010.
46. WOLPIN BM, MEYERHARDT JA, CHAN AT, et al: Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27: 176-185, 2009
47. MICHAUD DS, WOLPIN B, GIOVANNUCCI E, et al: Prediagnostic plasma c-peptide and pancreatic Cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16: 2101-2109, 2007.
48. BALKAU B, KAHN HS, COURBON D, ESCHWÈGE E, DUCIMETIÈRE P; Paris Prospective Study: Hyperinsulinemia predicts fatal liver Cancer but is inversely associated with fatal Cancer at some other sites: The Paris Prospective Study. Diabetes care 24: 843-849, 2001.
49. ELIASSEN AH, TWOROGER SS, MANTZOROS CS, POLLAK MN and HANKINSON SE: Circulating insulin and c-peptide levels and risk of breast Cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev 16: 161-164, 2007.
50. HIROSE K, TOYAMA T, IWATA H, TAKEZAKI T, HAMAJIMA N and TAJIMA K: Insulin, insulin-like growth factor-i and breast Cancer risk in japanese women. Asian Pac J Cancer Prev 4: 239-246, 2003.
51. LARSSON SC, MANTZOROS CS and WOLK A: Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer 121: 856-862, 2007.
52. CUST AE, ALLEN NE, RINALDI S, et al: Serum levels of c-peptide, igfBP-1 and igfBP-2 and endometrial Cancer risk; results from the european prospective investigation into Cancer and nutrition. Int J Cancer 120: 2656-2664, 2007.
53. LUKANOVA A, LUNDIN E, MICHELI A, et al: Risk of ovarian Cancer in relation to prediagnostic levels of c-peptide, insulin-like growth factor binding proteins-1 and-2 (uSa, Sweden, italy). Cancer causes control 14: 285-292, 2003.
54. LUKANOVA A, ZELENIUCH-JACQUOTTE A, LUNDIN E, et al: Prediagnostic levels of c-peptide, igf-i, igfBP-1,-2 and-3 and risk of endometrial cancer. Int J Cancer 108: 262-268, 2004.
55. KASPER JS and GIOVANNUCCI E: A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 2056-2062, 2006.
56. BORUGIAN MJ, SPINELLI JJ, SUN Z, et al: Prediagnostic c-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16: 2164-2165, 2007.
57. RODDAM AW, ALLEN NE, APPLEBY P, et al: Insulin-like growth factors, their binding proteins, and prostate Cancer risk: Analysis of individual patient data from 12 prospective studies. Ann intern Med 149: 461-471, w83-w88, 2008.
58. MA J, LI H, GIOVANNUCCI E, et al: Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specifc mortality in men with prostate cancer: A long-term survival analysis. Lancet Oncol 9: 1039-1047, 2008.
59. AHN J, WEINSTEIN SJ, SNYDER K, POLLAK MN, VIRTAMO J and ALBANES D: No association between serum insulin-like growth factor (igf)-i, igf-binding protein-3, and lung Cancer risk. Cancer Epidemiol Biomarkers Prev 15: 2010-2012, 2006.
60. LUKANOVA A, TONIOLO P, AKHMEDKHANOV A, et al: A prospective study of insulin-like growth factor-i, igf-binding proteins-1,-2 and-3 and lung Cancer risk in women. Int J Cancer 92: 888-892, 2001.
61. LONDON SJ, YUAN JM, TRAVLOS GS, et al: Insulin-like growth factor i, igf-binding protein 3, and lung Cancer risk in a prospective study of men in china. J Natl Cancer Inst 94: 749-754, 2002.
62. SPITZ MR, BARNETT MJ, GOODMAN GE, THORNQUIST MD, WU X and POLLAK M: Serum insulin-like growth factor (igf) and igf-binding protein levels and risk of lung cancer: A case-control study nested in the beta-carotene and retinol effcacy trial Cohort. Cancer Epidemiol Biomarkers Prev 11: 1413-1418, 2002.
63. JOSHI N, CAPUTO GM, WEITEKAMP MR and KARCHMER AW: Infections in patients with diabetes mellitus. N Engl J Med 341: 1906-1912, 1999.
64. MULLER LM, GORTER KJ, HAK E, et al: Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41: 281-288, 2005.
65. TAKAHASHI K, IWASE M, YAMASHITA K, et al: The elevation of natural killer Cell activity induced by laughter in a crossover designed study. Int J Mol Med 8: 645-650, 2001.
66. LI Q, KOBAYASHI M, INAGAKI H, et al: A day trip to a forest park increases human natural killer activity and the expression of anti-cancer proteins in male subjects. J Biol regul homeost agents 24: 157-165, 2010.
67. HAYASHI T, TSUJII S, IBURI T, et al: Laughter up-regulates the genes related to nK Cell activity in diabetes. Biomed Res 28: 281-285, 2007.
68. MAES M, MELTZER HY, STEVENS W, CALABRESE J and COSYNS P: Natural killer Cell activity in major depression: Relation to circulating natural killer cells, cellular indices of the immune response, and depressive phenomenology. Prog neuropsychopharmacol Biol Psychiatry 18: 717-730, 1994.
69. REICHE EM, NUNES SO and MORIMOTO HK: Stress, depression, the immune system, and cancer. Lancet Oncol 5: 617-625, 2004.
70. Kiessling R, Klein E, Pross H and Wigzell H: 'Natural' killer cells in the mouse. II. Cytotoxic cells with specifcity for mouse Moloney leukemia cells. characteristics of the killer cell. Eur J Immunol 5: 117-121, 1975.
71. KIESSLING R, PETRANYI G, KÄRRE K, JONDAL M, TRACEY D and WIGZELL H: Killer cells: A functional comparison between natural, immune t-cell and antibody-dependent in vitro systems. J Exp Med 143: 772-780, 1976.
72. RODER JC, KIESSLING R, BIBERFELD P and ANDERSSON B: Target-effector interaction in the natural killer (nK) Cell system. II. the isolation of NK cells and studies on the mechanism of killing. J Immunol 121: 2509-2517, 1978.
73. MORETTA L, BOTTINO C, PENDE D, VITALE M, MINGARI MC and MORETTA A: Human natural killer cells: Molecular mechanisms controlling nK Cell activation and tumor Cell lysis. Immunol lett 100: 7-13, 2005.
74. WALDHAUER I and STEINLE A: Nk cells and Cancer immunosur-veillance. Oncogene 27: 5932-5943, 2008.
75. FURUE H, MATSUO K, KUMIMOTO H, et al: Decreased risk of colorectal Cancer with the high natural killer Cell activity nKg2D genotype in japanese. Carcinogenesis 29: 316-320, 2008.
76. SZKARADKIEWICZ A, KARPINSKI TM, DREWS M, BOREJSZA-WYSOCKI M, MAJEWSKI P and ANDRZEJEWSKA E: Natural killer Cell cytotoxicity and immunosuppressive cytokines (il-10, tgf-beta1) in patients with gastric cancer. J Biomed Biotechnol 2010: 901564, 2010.
77. HAMMOND KJ, PELIKAN SB, CROWE NY, et al: Nkt cells are phenotypically and functionally diverse. Eur J Immunol 29: 3768-3781, 1999.
78. JERUD ES, BRICARD G and PORCELLI SA: Cd1D-restricted natural killer t cells: Roles in tumor immunosurveillance and tolerance. Transfus Med Hemother 33: 18-36, 2006.
79. MONTOYA CJ, POLLARD D, MARTINSON J, et al: Characterization of human invariant natural killer t subsets in health and disease using a novel invariant natural killer t cell-clonotypic monoclonal antibody, 6B11. Immunology 122: 1-14, 2007.
80. BALATO A, UNUTMAZ D and GASPARI AA: Natural killer t cells: An unconventional t-cell subset with diverse effector and regulatory functions. J Invest Dermatol 129: 1628-1642, 2009.
81. CHAN AC, SERWECINSKA L, COCHRANE A, HARRISON LC, GODFREY DI and BERZINS SP: Immune characterization of an individual with an exceptionally high natural killer t Cell frequency and her immediate family. Clin Exp Immunol 156: 238-245, 2009.
82. SMYTH MJ, THIA KY, STREET SE, et al: Differential tumor surveillance by natural killer (nK) and nKt cells. J Exp Med 191: 661-668, 2000.
83. MERCER JC, RAGIN MJ and AUGUST A: Natural killer t cells: Rapid responders controlling immunity and disease. Int J Biochem Cell Biol 37: 1337-1343, 2005.
84. BENDELAC A, SAVAGE PB and TEYTON L: The biology of nKt cells. Annu Rev Immunol 25: 297-336, 2007.
85. BERZOFSKY JA and TERABE M: The contrasting roles of nKt cells in tumor immunity. Curr Mol Med 9: 667-672, 2009.
86. SWANN JB, ULDRICH A P, VAN DOMMELEN S, et al: Type i natural killer t cells suppress tumors caused by p53 loss in mice. Blood 113: 6382-6385, 2009.
87. O'SHEA D, CAWOOD TJ, O'FARRELLY C and LYNCH L: Natural killer cells in obesity: Impaired function and increased susceptibility to the effects of cigarette smoke. PloS one 5: E8660, 2010.
88. LYNCH LA, O'CONNELL JM, KWASNIK AK, CAWOOD TJ, O'FARRELLY C and O'SHEA DB: Are natural killer cells protecting the metabol-ically healthy obese patient? Obesity (Silver Spring) 17: 601-605, 2009.
89. LYNCH L, O'SHEA D, WINTER DC, GEOGHEGAN J, DOHERTY DG and O'FARRELLY C: Invariant nKt cells and cD1d(+) cells amass in human omentum and are depleted in patients with Cancer and obesity. Eur J Immunol 39: 1893-1901, 2009.